IMUX - Immunic, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.41
+0.01 (+0.16%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.40
Open6.43
Bid6.40 x 1100
Ask7.65 x 900
Day's Range6.20 - 7.50
52 Week Range6.04 - 46.80
Volume50,551
Avg. Volume26,676
Market Cap64.85M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.01
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.00
  • PR Newswire

    Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay "Buck" A. Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019. With this addition, Immunic's Board will total seven members. "Buck's decades of relevant experience in the biotechnology sector, both as a Chief Financial Officer and investor, will add a unique perspective to our Board," stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic.

  • PR Newswire

    Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity

    NEW YORK , Nov. 7, 2019 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory ...

  • PR Newswire

    Immunic, Inc. to Participate in Industry and Investor Conferences in November

    November 11-13: 25th Annual BIO-Europe International Partnering Conference: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, on Tuesday, November 12, at 9:30 am CET. November 19-20: Stifel 2019 Healthcare Conference: Dr. Vitt will present a company overview at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19, at 8:35 am ET.

  • We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • PR Newswire

    Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

    SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson, a highly seasoned life sciences executive, to its Board of Directors, effective October 11, 2019. With this addition, Immunic's Board now totals six members. "Tamar brings to Immunic more than thirty years of relevant experience in corporate and business development, having worked in-house, and as a consultant and Board member for a wide range of companies in the biotechnology and pharmaceutical industries," stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic.

  • PR Newswire

    Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

    SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that the final patient was enrolled and randomized today in the company's phase 2 EMPhASIS trial of IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Patient enrollment was completed well ahead of the original trial schedule. "Achievement of this milestone for our lead program, IMU-838, in RRMS, substantially ahead of prior expectations, reflects not only our team's strength in executing on the company's drug development strategy, but also the urgent need from patients for a safer oral treatment option," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

  • PR Newswire

    Immunic, Inc. to Participate in Investor and Scientific Conferences in October

    October 2-4: 2019 Cantor Global Healthcare Conference: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the 2019 Cantor Global Healthcare Conference in New York on Friday, October 4, at 12:35 pm EDT. A live audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.immunic-therapeutics.com.

  • PR Newswire

    Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

    Immunic also plans to extend these studies to assess safety and mechanism-related biomarkers in patients with psoriasis. "The dosing of the first healthy volunteer in our phase 1 program of IMU-935 represents an important inflection point for Immunic, as we progress, on plan, with the development of this important pipeline candidate," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

  • PR Newswire

    Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Andreas Muehler, M.D., Chief Medical Officer of Immunic, will present today selected available and previously unpublished preclinical data summarizing the profile of its lead oral compound, IMU-838, as compared to the dihydroorotate dehydrogenase (DHODH) inhibitor, teriflunomide, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019 in Stockholm, Sweden. The poster will be presented during Poster Session 1 being held today, from 5:15 pm to 7:15 pm CEST. IMU-838, in phase 2 development for relapsing-remitting multiple sclerosis (RRMS) and ulcerative colitis, is a novel, orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking DHODH.

  • PR Newswire

    Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

    SAN DIEGO, Sept. 5, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the results of a pre-planned interim dosing analysis in the phase 2 CALDOSE-1 study of IMU-838 in patients with moderate-to-severe ulcerative colitis (UC). Based on the available data, an unblinded and independent data review committee has concluded that the study's lowest, 10 mg dose was found not to be likely ineffective and that the highest, 45 mg dose was not intolerable. The study's primary endpoint comprises a composite of a patient reported outcome and endoscopy-assessed outcome, both to be evaluated following ten weeks of induction treatment with IMU-838 or placebo.

  • PR Newswire

    Immunic, Inc. to Participate in Scientific and Investor Conferences in September

    SAN DIEGO , Sept. 3, 2019 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX),  a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of ...

  • PR Newswire

    Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis

    IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). PSC is a progressive disease of the liver with unknown cause and a prevalence of about 4.15 per 100,000 in the United States.

  • PR Newswire

    Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity

    SAN DIEGO , Aug. 8, 2019 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX),  a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chronic ...

  • PR Newswire

    Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project

    SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the German Federal Ministry of Education and Research has awarded its subsidiary, Immunic AG, a grant in the amount of up to EUR 653,535 (approximately USD 730,000) in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project. The InnoMuNiCH project is coordinated by BioM Biotech Cluster Development GmbH and supported by the Ministry of Education and Research, as part of the funding program, "Internationalization of Leading-Edge Clusters, Forward-Looking Projects and Other, Comparable Networks." The goal of the project is to accelerate global biopharmaceutical innovations by pooling German-Japanese competencies in research and development.

  • PR Newswire

    Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8

    SAN DIEGO, July 30, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Thursday, August 8, 2019 at 2:30 pm EDT. Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis.

  • Could Immunic, Inc.'s (NASDAQ:IMUX) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Immunic, Inc.'s (NASDAQ:IMUX) Investor Composition Influence The Stock Price?

    If you want to know who really controls Immunic, Inc. (NASDAQ:IMUX), then you'll have to look at the makeup of its...

  • PR Newswire

    Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer

    SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company's Interim Chief Financial Officer since April 26, 2019. With a deep well of C-Suite and investment banking experience, Sanjay's proven track record, strong knowledge base and established industry relationships will be especially important as we continue to move our pipeline, including our lead compound, IMU-838, through the clinic and prepare for a number of value-creating milestones in the coming year and beyond," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

  • PR Newswire

    Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston

    SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present today previously unpublished data regarding the company's lead program, IMU-838, at the GI Inflammatory Diseases Summit (GIIDS) in Boston. The presentation, entitled, "IMU-838 in Clinical Phase 2 – New Selective Oral Treatment for IBD," will take place at 3:30 pm ET. IMU-838, currently in phase 2 clinical development for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH).

  • PR Newswire

    Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

    SAN DIEGO, June 21, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has filed an amended Current Report on Form 8-K containing certain financial statements and pro forma financial information required to be provided in connection with the stock-for-stock exchange transaction between Immunic, Inc. (then known as Vital Therapies, Inc.) and Immunic AG, which was completed on April 12, 2019. Management also provided an update on the progress of its key development programs.

  • PR Newswire

    Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2ⁿᵈ Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway

    - Results confirm IMU-935 as a potent inverse agonist of ROR ϒt with an IC 50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation - - In addition to ...

  • PR Newswire

    Immunic, Inc. to Participate in Investor and Scientific Conferences in June

    June 3-6: 2nd Conference on Molecular Mechanisms of Inflammation: Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present newly available preclinical data on IMU-935, an orally available, inverse agonist of RORγt for the treatment of various inflammatory and autoimmune diseases. The poster presentation will take place at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway on Tuesday, June 4, beginning at 6:00 pm CEST.

  • PR Newswire

    Immunic, Inc. to Participate in Upcoming May Conferences

    May 18-21: Digestive Disease Week® (DDW): Dr. Andreas Muehler, Chief Medical Officer of Immunic, will attend the DDW conference, being held at the San Diego Convention Center in San Diego. May 20-21: BioEquity Europe 2019: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at 5:15 pm CEST on May 20 at the 20th Annual BioEquity Europe conference, being held at the Crowne Plaza Barcelona Fira Center Hotel in Barcelona, Spain.

  • PR Newswire

    Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer

    SAN DIEGO, April 29, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. "Ms. Seymour has a proven track record of guiding public and privately-held life sciences companies through their corporate life cycles, including capital raising, negotiating complex strategic transactions, setting and maintaining internal fiscal policy and driving revenue growth," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.